ITP - IMMUNE THROMBOCYTOPENIA
Clinical trials for ITP - IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new ITP - IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for ITP - IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited immune cells take on autoimmune blood diseases
Disease control Recruiting nowThis early-stage trial tests a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to safely control two autoimmune diseases where the body attacks its own blood cells: immune thrombocytopenia (ITP) and warm autoimmune hemolytic a…
Matched conditions: ITP - IMMUNE THROMBOCYTOPENIA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for teens with rare bleeding disorder: experimental drug enters final testing
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…
Matched conditions: ITP - IMMUNE THROMBOCYTOPENIA
Phase: PHASE2, PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug OM336 aims to tame overactive immune system
Disease control Recruiting nowThis early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried a…
Matched conditions: ITP - IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Ouro Medicines • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC